Press Releases
Circassia’s Extended Offer Period for Aerocrine has Increased Acceptances to 97.2 Percent
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...
View detailsCompletion of Acquisition of Prosonix Limited
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...
View detailsResults of the Placing and Open Offer
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...
View detailsPlacing and Open Offer of New Ordinary Shares
Click here to download the full Placing and Open Offer announcement THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY...
View detailsProposed Acquisitions of Aerocrine AB and Prosonix Limited Creating a World-Class Allergy and Asthma Specialty Pharma Business
Click here to download the full Proposed Acquisitions announcement NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN...
View detailsPreliminary Results for the Year Ended 31 December 2014
Click here to download the full 2014 preliminary results statement – Strong clinical progress; Cat-SPIRE phase III study fully recruited – – Robust financial position; fully-funded to bring Cat-SPIRE to market – – Commercialisation preparations...
View detailsCircassia Appoints Lota S Zoth as Non-Executive Director
Click here to download full press release Oxford, UK – 9 February 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces the appointment of Lota...
View detailsNotice of Preliminary Results
Oxford, UK – 27 January 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, will announce its preliminary results for the year ended 31 December 2014 on...
View detailsCircassia Completes Recruitment for Cat Allergy Treatment Pivotal Phase III Study
Click here to download full press release – Study on track to report in H1 2016 – – 1,409 subjects randomised; 19% above target – Oxford, UK – 8 January 2015: Circassia Pharmaceuticals plc (“Circassia”...
View detailsCircassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study
Click to download full press release Oxford, UK – 8 December 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces results from a phase IIb...
View details